direct effects of alcohol, its metabolites and reactive oxygen species produced during alcohol metabolism result in cellular stress in hepatocytes, release of damage-associated molecules (DAMPs) and increased hepatocyte vulnerability to inflammation-related cellular injury.
Excessive alcohol use also results in gut "leakiness" resulting in increased delivery of pathogenderived molecular patterns (PAMPs) to the liver via the portal system. All of these gut-derived PAMPs and hepatocyte-derived DAMPs contribute to Kupffer cell and innate immune cell activation in the liver in alcoholic liver disease (1) . Alcohol use was shown to change the composition of the gut microbiome by modifying the quantity, quality and diversity of bacteria in the intestines both in humans and mice (1) . The composition of the gut microbiome is only partially understood and it includes bacteria, fungi and viruses. Every individual's gastrointestinal tract contains thousands of different species of microbes of which 99.9% belong to only a few species. The less abundant component of the microbiome is termed as "rare biosphere" that is more diverse and appears to have a major impact on health and disease. The fungal microbiota, also referred to as "the mycobiome", is part of the rare biosphere and this is a new and rapidly emerging field on which scientific knowledge lags behind that of the bacterial microbiome. Increasing evidence suggests that the fungal microbiome plays a role as a cofactor in inflammatory and metabolic disorders and also in modulating the bacterial microbiome and host defense. The fungal microbiome has been studied at mucosal sites such as the oral cavity, gastrointestinal and urogenital tracts and the skin. Studies in healthy individuals revealed 66 different fungal genera in the fecal material where the most common genera were Saccharomyces, Candida, and Cladosporium (2) . Recent studies indicate correlation between changes in the gut mycobiome and different disease conditions. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.30055 showed that inhibition of IL-1 signaling and inflammasome activation with IL-1 receptor antagonist has a protective effect in a mouse model of alcoholic hepatitis (6) . As a follow-up of this discovery, treatment with anakinra, a recombinant human IL-1Ra, is now under investigation in an ongoing human clinical trial in human alcoholic liver disease (7) .
Looking forward, more questions than answers arise when assessing therapeutic implications of the basic research findings on the gut mycobiome in ALD. Although treatment with amphotericin B, a non-absorbable antifungal agent, was effective in mice to prevent alcohol-related liver damage, application of this approach in human disease awaits complex considerations.
Interestingly, β-1,3, glucan was suggested to provide health benefits in obesity and metabolic syndrome (8) . With the increasing understanding of the health effects of the "gut microbiota" (including bacteria, fungi and viruses), many questions remain unanswered on the interactions between the gut and liver in alcoholic liver disease. It remains to be determined whether the alcohol-related "leaky gut" is solely the result of alcohol and/or its metabolites on the gut mucosa or perhaps the gut microbiota also shapes this relationship. An additional aspect in alcohol use is the direct effect of the ingested alcohol on the intestinal microbiota itself and potential metabolism of alcohol by the intestinal microbiota. Finally, we need a better understanding of the dynamics and interactions between the various players including bacterial, fungal and viral components in the human "gut microbiota" that shapes health and disease in the host. activates Kupffer cells in the liver to induce interleukin-1ß production that in turn acts on hepatocytes to increase steatosis and promote hepatocyte injury.
Literature Cited

